In bid to keep it­self afloat, tiny Dif­fu­sion Phar­ma­ceu­ti­cals mulls out-li­cens­ing core tech or com­pa­ny sale

A Vir­ginia biotech is now look­ing at all its op­tions to keep it­self go­ing, even if that means sell­ing core com­pa­ny tech­nol­o­gy or even the com­pa­ny it­self.

Dif­fu­sion Phar­ma­ceu­ti­cals put out word Tues­day that its board of di­rec­tors, which in­cludes CEO Robert Cobuzzi, has au­tho­rized the com­pa­ny to re­view and eval­u­ate pos­si­ble strate­gic op­por­tu­ni­ties, as Dif­fu­sion put it, “in the in­ter­est of en­hanc­ing stock­hold­er val­ue” — in­clud­ing po­ten­tial trans­ac­tions to lever­age Dif­fu­sion’s can­di­dates and oth­er as­sets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER